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September 7, 2010:903–9ontinue, “A new dietary supplement . . . can be introduced and
arketed overnight . . . despite containing new, experimental, and
nregulated herbal ingredients” (1). Again, this statement is false.
f a manufacturer wishes to market a product that contains a new
erbal ingredient, there is a new dietary ingredient 75-day pre-
arket notification process in which safety data are supplied to the
DA for review (4). Similarly, the investigators claim that manu-
acturers are “exempt . . . from any post-marketing surveillance”
1), while in reality, this responsibility is assigned to both the FDA
nd the Federal Trade Commission. Furthermore, the investiga-
ors suggest that manufacturers do not comply with adverse event
eporting law, noting that “between 1990–94, fewer than 10 of
ore than 2,500 reports of adverse effects made to the FDA came
rom herbal product manufacturers” (1). These data, which predate
oth the law requiring the reporting of serious adverse events
2006) and DSHEA (1994), present a skewed view of industry
ompliance.
The investigators suggest a lack of regulation whereby an herbal
ngredient can be introduced to the market without restriction, no
ost-market surveillance is conducted, and herbals present a
isproportional risk to patients. DSHEA, serious adverse event
eporting, and good manufacturing practices for dietary supple-
ents, introduced by the FDA in 2007 but mandated by DSHEA
n 1994, provide a strong and appropriate regulatory framework for
he dietary supplement industry in the U.S. Despite these ad-
ances, potential drug-herb interactions will continue to present
hallenges to practicing clinicians. Thus, to meet patients’ expec-
ations, clinicians need a clear and factual presentation of the
egulatory background of herbal supplement products and a
houghtful evaluation of defined and theoretical contraindications
nd drug interactions affecting patients being treated for cardio-
ascular diseases. This review is a step backward in opening up a
ialogue between clinicians and patients on the topic of herbal
roducts.
M. Hafeez Chaudhry, MD
The Heart Center
610 Carroll Avenue, Suite 300
akoma Park, Maryland 20912
-mail: dchaudhry@aol.com
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e thank Drs. Asher, Dentali, and Chaudhry for their interest in
ur review (1) and for their critical comments. The intent of our
eview, written for cardiologists and other health care providers,
as to provide practical information about issues related to the use
f herbal products in patients with cardiovascular diseases. We
resented the information in easy-to-follow language, minimizing
echnical jargon, to remind busy practicing physicians to ask their
atients about the use of herbal products that could potentially
ncrease adverse drug reactions, including catastrophic events, such
s major bleeds, transplanted organ rejection, predisposition to
ife-threatening arrhythmias, or reductions in the efficacy of
edications used. The review has been received with great
nthusiasm from practicing cardiologists and other health care
roviders but also has generated criticism, mainly from practitio-
ers and from supporters and manufacturers of herbal products.
We thank Dr. Dentali for his comments regarding the impor-
ance of doctor–patient communication and the need for education
bout herbal products, and we appreciate the efforts of the
merican Herbal Products Association to educate the public about
heir use. We were surprised at and disappointed in the comments
egarding our discussion of issues such as a lack of quality control,
dvertising (public misinformation arising from the promotion of
upplements without scientific evidence for their efficacy and
afety), and the regulation of herbal supplements, which have
irect implications for public health. Dr. Dentali’s statement about
he report on colchicine in the placentas of women taking gingko
2) being erroneous is not discredited by the citations provided. In
ur review, we did not raise the issue of whether colchicine can be
ound naturally in ginkgo but in the context of quality control,
ontamination, and adulteration of herbal products (1). In the
eport we cited (2), colchicine was identified by sophisticated
nalytical techniques in placental blood from 5 women who used
erbal supplements but not from 19 nonusers. A significant
mount of colchicine (26  3 g/tablet) was also detected in
ingko biloba purchased from a local market in the Detroit area. In
he Li et al. (3) study, cited by Dr. Dentali, gingko biloba
urchased from pharmacies in Chicago did not reveal any signif-
cant colchicine levels. These findings and other studies indicate an
bsence of colchicine in naturally occurring gingko but do not rule
ut contamination or adulteration, an issue reported with several
erbal products (4–12). The information on the neonatal death is
rom a monograph on ginseng prepared by the Natural Standard
esearch Collaboration (13) and is available at the Medline Plus
ebsite, a service of the U.S. National Library of Medicine and the
ational Institutes of Health. We apologize for the confusion
rom this report that we cited and are thankful to Dr. Dentali for
ointing out the issue of mislabeling (likely adulteration) of
hinese silk vine (Periploca sepium) sold as Siberian ginseng (14).
he effect of black cohosh on cytochrome P450 (CYP) 3A4 has
een demonstrated by several investigators (15–17) and the con-
tituents of the commercially available black cohosh (Cimicifuga
acemosa) that causes the inhibition of human CYP 3A4 identified
15) as triterpene glycosides with weak effect and fukinolic acid and
imicifugic acids A and B as strong inhibitors of 4 CYP isozymes
1A2, 2D6, 2C9, and 3A4) (16). The inhibitory effect of black
ohosh was again confirmed recently by Sevior et al. (17). The
eason for the discrepancy in the reports cited by Dr. Dentali is
nclear. The Dietary Supplement Information Expert Committee
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September 7, 2010:903–9f the U.S. Pharmacopeia’s Council of Experts reviewed safety
nformation for black cohosh products after regulatory agencies in
he European Union, Canada, and Australia released statements
egarding a potential association between black cohosh and hepa-
otoxicity. The conclusion of this committee was that black cohosh
roducts should be labeled to include a cautionary statement, a
onsiderable change from a 2002 decision that required no such
tatement (18). Several sources were cited in the review regarding
he potential for increased risk for bleeding (references 4, 5, 8, 9,
2–34, 43, and 49 in the review). With limitations to the total
ord count of the manuscript and references, not every single
tudy could be cited, and a number of references were removed to
eet the required word count. With regard to digoxin, interactions
ith herbal compounds that interfere with digoxin assay were
isted in Table 4, and a reference to Dasgupta’s (19) report was
rovided.
We disagree with Dr. Asher’s comments on a leveling off of the
se of herbal products. A recently published report (20) from the
ational Health Interview Survey conducted by the Centers for
isease Control and Prevention, the National Center for Health
tatistics, and the National Institutes of Health indicates that the
se of self-care complementary and alternative medicine (CAM)
herapies is on the rise. Compared with the last national estimates
n the cost of CAM, conducted more than 10 years ago (21), the
ut-of-pocket expense of self-care therapies had increased mark-
dly. Almost two-thirds of out-of-pocket CAM costs were asso-
iated with self-care therapies, with the majority spent on nonvi-
amin, nonmineral, natural products that amounted to 31% of
hat the public spent out of pocket to buy pharmaceutical drugs in
007. The findings in this report of more than a 2-fold increase in
he cost estimate of nonvitamin, nonmineral, natural products
$14.8 billion) to that ($6.6 billion) estimated by Eisenberg et al.
21) a decade ago suggests a dramatic increase in their use. This
onclusion is consistent with industry sales reports indicating a
arge increase in spending for nonvitamin, nonmineral, natural
roducts between 1997 and 2007 (22) and in 2008 with U.S.
onsumer sales of dietary supplements reported at $25 billion (23).
esearch reported in the Nutrition Business Journal found that
unlike most other segments of the economy, the U.S. nutrition
ndustry continues to expand at a double-digit pace—and ended
007 with its highest growth rate in nine years. Nutrition Business
ournal research shows that, in 2007, the U.S. nutrition industry
rew 10.7%—almost a full percentage point higher than in 2006”
24). It can be easily deduced that the consumption of these
upplements continues to rise.
We were surprised at Dr. Asher’s comments about missing the
umber of adults consuming herbal remedies, which we mentioned
n the opening paragraph of our review and later with other
nformation from the survey conducted by Eisenberg et al. (21).
e also disagree with Dr. Asher’s statement that the discussion of
erb and drug metabolism was potentially misleading. We would
ike to remind Dr. Asher, and refer him to several studies
15,25–29) and textbook chapters (30,31), about the importance of
YP 3A4, the most abundant CYP isozyme in the liver, estimated
o be involved in the metabolism of about 50% of the currently
arketed therapeutics (25,29) that catalyze reactions involving
1,000 exogenous and endogenous compounds. The study cited
y Dr. Asher (Shimada et al. [32]) immunochemically character-
zed CYP in 60 patients and found CYP 3A4 to represent about
0% of total CYP, but those investigators did not assess the
roportions of drugs metabolized by various subtypes of CYP snzymes. Besides, detailed medical and drug histories were not
nown in many patients, and no consideration was made of disease
tates and drug intake, which can significantly alter the expression
evels of enzymes. In our review, we emphasized that caution be
aken when compounds that can significantly affect the activity of
YP 3A4, when coadministered with substrate of this enzyme,
ecause it can result in elevated blood levels. One of the main
essages of our review was to encourage medical practitioners to
outinely ask for information about CAM use when they take drug
istories and to include herbal and dietary supplement products in
dverse drug and herb event reports. In addition, we highlighted
he need to conduct scientific studies to gather more information
n such herb-drug interactions, which will not be recognized
nless a formal system of reporting to gather scientific information
s implemented. This is also emphasized in an Institute of
edicine report (33). With regard to sertraline, we would like to
ring to the attention of Dr. Asher a study by Ueda et al. (34) using
crossover design in healthy subjects given grapefruit juice or
ater and then sertraline 75 mg on day 6, demonstrating a
ignificant increase in mean peak plasma sertraline concentration
from 17.6  6.1 to 29.3  11.5 ng/ml) and the mean area under
he plasma sertraline concentration-time curve from zero to infin-
ty of sertraline from 402  152 to 820  313 h·ng/ml.
We cited the Cochrane systematic review “Hawthorn Extract
or Treating Chronic Heart Failure” by Pittler et al. (35), which
ncluded 14 trials that used hawthorn as an adjunct to conventional
reatment for heart failure (mostly patients with mild [New York
eart Association functional class II] heart failure). In the Tan-
anow et al. (36) study, enrolling 8 healthy volunteers with a mean
ge of 28  6 years and no cardiac conditions, hawthorn given for
1 days with digoxin resulted in a modest decrease in absorption
nd an increase in the clearance of digoxin, presumably related to
he mild induction of P-glycoprotein activity. The findings of this
hort-term study in young healthy volunteers do not prove the
afety of hawthorn in a typical patient with heart failure as seen in
ur clinical practice, who is old with multiple comorbidities and on
any medications that can affect the pharmacokinetics and phar-
acodynamics of digoxin and other drugs. In the systemic review
f 14 trials by Pittler et al. (35), the duration of treatment was
hort, ranging from 3 to 16 weeks, and only a limited number of
atients were enrolled in each of the randomized trials. Ten trials
eported the use of concomitant drugs. Diuretics were allowed in
trials, and angiotensin-converting enzyme inhibitors were al-
owed in only 3 trials. Significant improvements in symptom
ontrol and physiologic outcomes from hawthorn extract over
lacebo were observed. However, other heart failure treatments
atients received were not described in some, and no data on
ortality and cardiac events were reported, except for 1 trial
eporting 3 deaths in the active group and 1 in the control group,
ith no further details. The investigators were cautious because of
he small number of studies, with potential incompleteness of the
eviewed evidence and potential publication and location bias
37–39), and concluded, “We believe that hawthorn extracts are
ot ideal candidates for the over-the-counter market” (35), similar
o what we suggested in our review. We stand by our statement
hat no scientifically valid safety assessment of the long-term use of
awthorn exists in a large number of elderly patients with heart
ailure, a condition requiring chronic use of hawthorn and other
edications. A systematic review of published reports does not
ecessarily mean that the efficacy or safety of a product has been
cientifically assessed in a randomized, placebo-controlled, double-
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September 7, 2010:903–9lind manner. Information about the pharmacokinetics, pharma-
odynamics, efficacy, and safety of herbal products in the popula-
ion with cardiovascular diseases (40) who also have multiple
omorbidities and take different medicines, including those with
arrow therapeutic indexes (41), is particularly limited. With
egard to hawthorn, when the manufacturers were asked by
aniele et al. (42) (the study cited by Dr. Asher) to provide safety
nformation, most did not respond, and no satisfactory data were
rovided by the remaining. The lack of safety data in cardiovas-
ular patients is a recurring phenomenon in herbal medicine, with
o rigorous attention given to adverse events or interactions with
rescription drugs. Even when data are available in other popula-
ions, typically healthy volunteers or low-risk patients without
omorbid conditions, findings are often questionable because of a
ack of consistency in research methods, small numbers of subjects,
he absence of placebo groups, a lack of standardization of
upplements, and an absence of data about drug-herb interactions.
hus, findings for specific herbal products are of limited usefulness
or making decisions about efficacy or safety.
We would like to remind Dr. Chaudhry of the shortcomings
nd loopholes in the Dietary Supplement Health and Education
ct of 1994, which required subsequent modifications and regu-
ations in the form of the final rule on current good manufacturing
ractices for dietary supplements (43,44), the Dietary Supplement
nd Nonprescription Drug Consumer Protection Act (45), and a
ecent move by legislators (46) to propose additional safety
easures to protect public health from adulterations of dietary and
erbal supplements. However, it was regrettable to see how vested
nterest groups and lobbies aggressively opposed the recently
roposed reforms (47) and attempts to bring the issues related to
upplement-drug safety for public discussion and review by health
are community. It is a surprise that Dr. Chaudhry objects to the
iscussion of grapefruit juice, a plant product commonly used for
ts medicinal effect, in our review. It is well documented that
rapefruit juice significantly inhibits hepatic and enterocyte
YP 3A4 enzymatic activity (48), and its simultaneous consump-
ion with medications may result in their elevated blood levels and
otential toxicity with those used commonly by our patients,
ncluding statins, calcium-channel blockers, antiarrhythmic agents,
mmunosuppressive drugs, and retroviral agents (49–52), and
herefore discussion of these interactions is important and relevant.
Although the Dietary Supplement Health and Education Act
equires the manufacturers or distributors of dietary supplements
o be responsible for determining the safety of their products and
ny representations or claims made about them, there is no
egulation or law that requires manufacturers to provide the U.S.
ood and Drug Administration (FDA) with the evidence the
anufacturers rely on to substantiate safety or effectiveness before
r after marketing them. Unlike drugs, which must be proven safe
nd effective for their intended use before marketing, dietary
upplements can be marketed without FDA approval, including
vernight sale as new formulations or combinations of products
hat have been in the market since before 1994. The exception is
or “new dietary ingredients,” defined by the Dietary Supplement
ealth and Education Act as those not sold in the U.S. before
ctober 15, 1994, which do require 75 day pre-market notification
nd review for safety data (53). Despite this requirement, the FDA
oes not provide guidance as to what specific information the
ubmission for new dietary ingredients must contain. The manu-
acturers or distributors are responsible for determining what data
rovide the basis for their conclusions of safety and efficacy, not mandated clinical studies. Because there is no authoritative list of
ietary ingredients that were marketed in dietary supplements
efore October 15, 1994, the manufacturers or distributors are
esponsible for determining if ingredients are new dietary ingre-
ients and, if not, for documenting that dietary supplements that
ontain the dietary ingredients were marketed before October 15,
994. Without adequate documentation of what was marketed
efore that date, it is difficult to enforce this rule.
The FDA guidelines for manufacturers mandate that they avoid
ontaminating products with other herbs, pesticides, heavy metals,
r prescription drugs (54). Nonetheless, even after the enactment
f the Dietary Supplement and Nonprescription Drug Consumer
rotection Act in 2006, dietary supplements have been repeatedly
eported to contain adulterant compounds and to put unknowing
onsumers at risk for adverse side effects and drug interactions.
eports of adulteration in dietary supplements with pharmaceuti-
als such as sibutramine with the potential for abuse or addiction
nd elevations in blood pressure and heart rate that pose significant
isk to patients with heart disease, heart failure, arrhythmias, or
troke continue (4), with the most recent report published just last
onth by Vaysse et al. (55). In an analysis of 20 herbal and dietary
upplements marketed as natural slimming products, 8 formula-
ions were found to contain sibutramine, 5 sibutramine with
henolphthalein, and 1 adulterated with synephrine (55). Despite
ewer regulations, adulteration of vitamins and nutritional supple-
ents with anabolic steroids (56) and other pharmaceuticals (5,57)
s well as contamination with microbial agents (8), metals (6), and
ther compounds (9,10) continues to be a problem. Several cases of
otentially life threatening hepatotoxicity (leading to liver trans-
lantation in some) attributed to Herbalife products marketed for
romoting energy, fitness, and weight control were recently doc-
mented (9,11). The issue of interactions with pharmaceutical or
ther botanical agents is not addressed or systematically assessed,
articularly in the vulnerable population, including the elderly with
ardiovascular diseases. No package inserts for herbal supplements
escribing potential adverse events or drug interactions are re-
uired, and patients have no way of distinguishing safe from
otentially harmful supplements they can take with their medi-
ines. We continue to see direct-to-consumer advertisements with
xtravagant claims in the popular media by the dietary supplement
ndustry, with unsubstantiated and dubious health claims (58),
uch as the prevention of aging, the preservation of youth, and the
revention and treatment of cardiovascular conditions. Does put-
ing a disclaimer in fine print on labels and in advertisements that
these statements have not been evaluated by the FDA” and that
this product is not intended to diagnose, treat, cure, or pre-
ent disease” give a manufacturer or distributor license to sell and
rofit from compounds that could potentially harm the health or
nances of the public? The Federal Trade Commission provides
versight and guidance but relies on advertisement surveillance for
nforcement of its guidelines rather than approving a product
efore its use. Thus, despite the levying of millions of dollars in
nes yearly by the Federal Trade Commission, misleading adver-
isements continue to thrive (43).
With regard to post-marketing surveillance, the sale of herbal
upplements can be halted by FDA only if the products have been
roven dangerous or shown to be “unsafe,” before the FDA can
ake action to restrict the products’ use or remove them from the
arketplace (59). With the limited resources available to FDA,
outine testing of food supplements, with 1,800 manufacturers and
ore than 75,000 products in the market (43), enforcement of the
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September 7, 2010:903–9xisting laws is not possible (60), and the FDA cannot fully
ccomplish its mission of consumer protection without increases in
esources and regulations on the industry. The burden of proof for
emonstrating that supplements are safe must be placed on
anufacturers rather than the government or consumers. In June
007, the FDA published comprehensive regulations for current
ood manufacturing practices for dietary supplements (44) that
stablish the minimum current good manufacturing practices for
he manufacture, packaging, labeling, or holding of dietary sup-
lements to ensure their quality. However, without validated
nalytical standards and methods to detect the active ingredients of
he vast majority of herbal supplements, it will be difficult to detect
otency or dosing requirements for the products, with the added
omplication of marked batch-to-batch variability. The final rule
n current good manufacturing practices requires that manufac-
urers, not the FDA, determine the quality specifications for their
roducts, and companies that want to use less stringent specifica-
ions can do so without penalty (43). The enforcement of the final
ule will be challenging given the limited resources at the disposal
f the FDA for dietary supplement oversight (61).
Recent FDA post-marketing guidance for the supplement
ndustry mandates the reporting of serious adverse events to the
DA within 15 days, as we have mentioned (62). The absence of
re-marketing safety assessments puts the FDA in a position to act
nly after the fact, when substantial harm has already occurred.
resenting evidence to the FDA to provide reasonable assurance of
afety before marketing will improve consumer safety and will also
e beneficial for the supplement industry, but this is opposed by
he industry. The recently proposed Dietary Supplement Safety
ct of 2010 (46) will improve some of the shortcomings in the
xisting regulations by requiring manufacturers to list all ingredi-
nts on the packaging and mandating the registering of all dietary
anufacturers with the FDA to ensure that the FDA knows what
s being sold and providing mandatory recall authority of any
ietary supplement if the FDA finds it to be hazardous to public
ealth, but opposition from vested interest groups will not allow
asy passage of these commonsense public safety regulations (47).
We agree with Drs. Asher, Dentali, and Chaudhry regarding
he need for a thoughtful evaluation of issues related to the use of
erbal products in patients with cardiovascular (and other chronic)
onditions. This will require a close dialogue among all parties
nvolved, including health care providers, pharmacists, consumers,
anufacturers of herbal products, and regulatory agencies, in an
bjective, professional, and respectful manner to assess the evi-
ence, on the basis of scientific methods free of prejudice, bias,
igotry, and petty self-interest, so that the true role of herbal
roducts as alternatives or complements to conventional medicine
an be established.
Arshad Jahangir, MD
iqar Maria, MD
ra Tachjian, MD
Mayo Clinic
3400 East Shea Boulevard
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